Why ‘time-to-value’ is the #1 metric for AI startups

AI continues to dominate digital health funding, but investors and health systems are demanding proof that these tools actually save money — and quickly. AI startups without clear, measurable ROI are finding it harder to stand out, explained Vig Chandramouli, partner at Oak HC/FT.

Editor's Pick

Top Story Why 'Time-to-Value' Is the #1 Metric Healthcare AI Customers Care About AI continues to dominate digital health funding, but investors and health systems are demanding proof that these tools actually save money — and quickly. AI startups without clear, measurable ROI are finding it harder to stand out, explained Vig Chandramouli, partner at Oak HC/FT. Sponsored Upcoming Webinar. ROI Reality Check: Separating Hype from Health Impact Presented by Solera Health Stop wasting budget on unproven trends. We calculate the hidden cost of digital hype, revealing how it drives opportunity cost, wasted dollars, and erodes employee trust when initiatives fail to deliver. Discover how to reallocate capital and focus on what truly moves the needle for your business.  Register now and join us on November 19th!

Featured News

As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities [Sponsored] In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play. UHC Taps Aeroflow Health for Virtual Nutrition Services UnitedHealthcare has partnered with Aeroflow Health to provide virtual, dietitian-led nutrition services for members managing chronic conditions. UCB Drug Becomes First FDA-Approved Treatment for Ultra-Rare and Fatal Mitochondrial Disease The FDA has approved UCB's Kygevvi for treating children and adults with thymidine kinase 2 deficiency, an inherited mitochondrial disorder. It's the drugmaker's first ultra-rare disease product. Oncologists Turn To Genomics For Improved Answers Genomic technologies not only help to identify cancers, but also offer opportunities for assessing the potential efficacy of different treatment options. By analyzing the genomic profile of a particular patient, doctors can see which medications might offer the most support, and which could cause more harm. The Future of Specialty Care: APPs, MDs, and Machine-Guided Supervision Many of today's systems weren't built for speed, supervision, or scale, and they can't support the level of intelligence or flexibility that modern care delivery demands. The solution isn't to retreat from APPs. It's to invest in models that make their work safe, effective, and scalable.

Video   Crypto in Healthcare Have you considered buying crypto as a corporate finance strategy? MedCity News' Debunked weighs in.

Resources

MedCity Pivot Podcast: A Chat With AWS Chief Medical Officer Rowland Illing Dr. Rowland Illing explained how life science companies and health systems are leveraing AWS HealthLake to transform healthcare. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe